Human Metabolome Technologies Equity 2024

Human Metabolome Technologies Aktienanalyse

What does Human Metabolome Technologies do?

Human Metabolome Technologies Inc (HMT) is a Japanese company specializing in the research and development of metabolome analysis. HMT was founded in 2000 with the vision of gaining a deeper understanding of the metabolic processes of the human body in order to contribute to better healthcare. HMT's business model involves conducting metabolome analysis using mass spectrometry and other technologies to characterize the body's metabolic processes. This includes analyzing both healthy and diseased metabolism from samples such as blood, urine, or tissue in large numbers to identify biomarkers or signatures that can be used in the early detection, diagnosis, prognosis, and treatment of diseases. In this sense, HMT serves as an important partner for researchers in the pharmaceutical and biomedical industry who want to develop new diagnostic and therapeutic approaches. In recent years, HMT has developed a wide range of metabolome analysis technologies tailored to various applications. One of HMT's most important products is the Targeted Metabolomics Platform, which allows for the quantification of a variety of metabolites in samples such as blood or urine. This is an important step towards developing biomarkers that can serve as indicators of an organism's metabolic state. Another important platform of HMT is the Biomarker Discovery Platform, which specializes in the identification of biomarkers associated with specific diseases. This platform is often used by pharmaceutical companies to develop new drugs tailored to the specific needs of patients with certain diseases. HMT has also developed a comprehensive metabolome database that allows researchers and analysts to compare their own data with a variety of reference data. This database contains information on thousands of metabolites and allows researchers to better understand metabolic pathways and biomolecular interactions. In recent years, HMT has also increased its investment in clinical research to explore the potentials of metabolome analysis in the diagnosis and treatment of cancer, diabetes, cardiovascular diseases, metabolic disorders, and other diseases. In collaboration with clinics and universities, HMT has conducted several clinical studies to evaluate the effectiveness of metabolome analysis in the early detection and monitoring of diseases. HMT is headquartered in Tsuruoka, Japan, and is also active in the US, Europe, and Asia. The company employs over 100 people and has become a leading provider of metabolome analysis and services. In summary, HMT has developed unique expertise in the field of metabolome analysis and is able to offer a wide range of products and services to support researchers and analysts in the study of the metabolic processes of the human body. With a strong emphasis on innovation and clinical research, HMT will continue to play an important role in the development of new diagnostic and therapeutic approaches tailored to the specific needs of patients. Human Metabolome Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Human Metabolome Technologies's Equity

Human Metabolome Technologies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Human Metabolome Technologies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Human Metabolome Technologies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Human Metabolome Technologies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Human Metabolome Technologies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Human Metabolome Technologies stock

What is the equity of Human Metabolome Technologies this year?

Human Metabolome Technologies has equity of 1.95 B JPY this year.

What was the equity of Human Metabolome Technologies compared to the previous year?

The equity of Human Metabolome Technologies has increased/decreased by 30.95% increased compared to the previous year.

What impact does a high equity have on investors of Human Metabolome Technologies?

A high equity is advantageous for investors of Human Metabolome Technologies as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Human Metabolome Technologies?

A low equity can be a risk for investors of Human Metabolome Technologies, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Human Metabolome Technologies affect the company?

An increase in equity of Human Metabolome Technologies can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Human Metabolome Technologies affect the company?

A reduction in equity of Human Metabolome Technologies can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Human Metabolome Technologies?

Some factors that can affect the equity of Human Metabolome Technologies include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Human Metabolome Technologies so important for investors?

The equity of Human Metabolome Technologies is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Human Metabolome Technologies take to change the equity?

To change equity, Human Metabolome Technologies can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Human Metabolome Technologies pay?

Over the past 12 months, Human Metabolome Technologies paid a dividend of 15 JPY . This corresponds to a dividend yield of about 2.48 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 15 JPY.

What is the dividend yield of Human Metabolome Technologies?

The current dividend yield of Human Metabolome Technologies is 2.48 %.

When does Human Metabolome Technologies pay dividends?

Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Human Metabolome Technologies?

Human Metabolome Technologies paid dividends every year for the past 0 years.

What is the dividend of Human Metabolome Technologies?

For the upcoming 12 months, dividends amounting to 15 JPY are expected. This corresponds to a dividend yield of 2.48 %.

In which sector is Human Metabolome Technologies located?

Human Metabolome Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Human Metabolome Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Human Metabolome Technologies pay the last dividend?

The last dividend was paid out on 9/1/2024.

What was the dividend of Human Metabolome Technologies in the year 2023?

In the year 2023, Human Metabolome Technologies distributed 10 JPY as dividends.

In which currency does Human Metabolome Technologies pay out the dividend?

The dividends of Human Metabolome Technologies are distributed in JPY.